Headline
The latest stories from AHA Today.
John Riggi, AHA’s national advisor for cybersecurity and risk, reviews key takeaways and insights from a recent AHA webinar on the importance of cyber preparedness.
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in the program’s price negotiations, the Centers for Medicare & Medicaid Services announced.
The Federal Emergency Management Agency resumed processing disaster relief funding for over 2,400 projects, including vital funding for hospitals, thanks to $16 billion provided to the agency in the continuing resolution funding the government through Nov. 17.
The Department of Health and Human Services’ Advanced Research Projects Agency for Health (ARPA-H) recently awarded $50 million in funding for six research projects to advance technologies that could help secure health care data.
“A recent article in the Wall Street Journal wants you to believe that many of our nation’s emergency departments are incapable of caring for children,” writes Chris DeRienzo, M.D., AHA senior vice president and chief physician executive.
The Senate Saturday passed a continuing resolution funding the government through Nov. 17 and avoiding a government shutdown.
The Organ Donation and Transplantation Alliance yesterday presented its Transformational Leader Award to Nancy Foster, AHA’s vice president for quality and patient safety policy.
Learn how Baltimore-based Mercy Medical Center’s Blue Dot Human Trafficking Initiative identifies and protects potential victims of human trafficking while encouraging them to come forward for help.
The departments of Health and Human Services, Labor, and the Treasury today released a request for information on the potential benefits and costs of requiring non-grandfathered health plans to cover over-the-counter preventive items and services without cost sharing and without a prescription.
The Food and Drug Administration Sept. 29 released a proposed rule that would phase out over four years its general enforcement discretion approach for most laboratory developed tests, citing concern that some of the tests may not provide accurate results or perform as well as FDA-approved in vitro…